Alexander Rosén Files SC 13D for Jupiter Neurosciences

TL;DR

**ROSEN BUYS JUPITER NEUROSCIENCES STOCK - 13D FILED**

AI Summary

On November 8, 2024, Alexander Rosén filed a Schedule 13D for Jupiter Neurosciences, Inc. This filing indicates a change in beneficial ownership of the company's common stock. Rosén's address is listed as 1001 North US HWY 1, Suite 504, Jupiter, Florida.

Why It Matters

This filing signals a potential shift in control or significant stake-building by Alexander Rosén in Jupiter Neurosciences, Inc., which could impact the company's stock price and strategic direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant stake accumulation or changes in control, which can lead to increased volatility and uncertainty for investors.

Key Players & Entities

• Jupiter Neurosciences, Inc. (company) — Subject Company
• Alexander Rosén (person) — Filing Person
• Rosen Alexander Gustaf Erik (person) — Filing Person
• Jupiter Orphan Therapeutics, Inc. (company) — Former Company Name

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
• $0.001 — Reporting Person as founders shares for $0.001 per share in cash in 2016, (ii) 56,250
• $500 — tions for which he paid an aggregate of $500 in May 2018, and (ii) 18,750 shares of
• $100 — re acquired by the Reporting Person for $100 in cash in April 2020. Fully vested s
• $0.74 — ncentive Plan with an exercise price of $0.74 and $0.80 per share, respectively. Per
• $0.80 — lan with an exercise price of $0.74 and $0.80 per share, respectively. Per the Report
• $1.33 — July 14, 2022 with an exercise price of $1.33. These options are fully vested. On J
• $128,810 — the Reporting Person agreed to forgive $128,810 of earned compensation in exchange for
• $477,382 — the Reporting Person agreed to forgive $477,382 of earned compensation in exchange for
• $59,298 — ck, 142,316 restricted stock units, and $59,298 to be paid out as a bonus upon an IPO.

Filing Documents

• formsc13d.htm (SC 13D) — 66KB
• ex10-1.htm (EX-10.1) — 21KB
• 0001493152-24-046384.txt ( ) — 89KB

From the Filing

SC 13D 1 formsc13d.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Jupiter Neurosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 48208B203 (CUSIP Number) Alexander Rosén 1001 North US HWY 1, Suite 504 Jupiter, Florida 33477 Phone: (561) 406-6154 (Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications) November 8, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 48208B203 1 NAMES OF REPORTING PERSON Alexander Rosén 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) 6 CITIZENSHIP OR PLACE OF ORGANIZATION United NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 1,789,100 * 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 1,789,100 * 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,789,100 * 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.7% ** 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN * Represents (i) 356,250 shares of Issuer’s common stock (“common stock”), (ii) 1,171,688 shares of common stock issuable upon exercise of stock options, (iii) 96,608 shares of common stock pursuant to a restricted stock award grant, and (iv) 164,554 shares of common stock pursuant to a restricted stock unit grant. ** Based on 30,126,413 shares of common stock issued and outstanding as disclosed in the Issuer’s Pre-Effective Amendment No. 21 to Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the “ SEC ”) on September 13, 2024, and calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, which requires that calculations be made for a stockholder assuming that such stockholder has exercised its exercisable securities but that no other stockholder has exercised or converted its exercisable or convertible securities. The Reporting Person in this filing has taken a different approach to calculating percentage ownership, assuming the vesting of his outstanding unvested shares of common stock pursuant to his restricted stock awards and restricted stock units. 2 Item 1. Security and Issuer This Jupiter Neurosciences, Inc., a Delaware corporation (the “ Issuer ”), which has its principal executive offices at 1001 North US HWY 1, Suite 504, Jupiter, Florida 33477. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Item 2. Identity and Background (a) The reporting person’s name is Alexander Rosén (the “ Reporting Person ”). (b) The reporting person’s address is c/o Jupiter Neurosciences, Inc., 1001 North US HWY 1, Suite 504, Jupiter, Florida 33477. (c) The reporting person is the Chief Administrative Officer of the Issuer. (d) The reporting person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) The reporting person was not, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which the reporting person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or a finding of any violatio

View Full Filing

View this SC 13D filing on SEC EDGAR